Abcam downgraded by RBC Capital Mkts with a new price target
$ABCM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
RBC Capital Mkts downgraded Abcam from Outperform to Sector Perform and set a new price target of $22.00 from $23.00 previously